PROPHETIC V07
Research type
Research Study
Full title
PROPHETIC – Predicting responsiveness in oncology patients based on host response evaluation during anti cancer treatments
IRAS ID
290564
Contact name
David C. Farrugia
Contact email
Sponsor organisation
Oncohost
Clinicaltrials.gov Identifier
NCT04056247, ClinicalTrials.gov Identifier; MOH_2019-10-06_007311, Israeli ministry of health identifier
Duration of Study in the UK
4 years, 0 months, 1 days
Research summary
PROPHETIC is a clinical study conducted in many sites around the world aimed to predict response to treatment of patients with stage IV non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and Malignant melanoma receiving anti-cancer therapy. This is done by collecting a blood sample before and after the first dose of treatment, and testing it in the laboratory. The laboratory test provides a list of the proteins (protein profile) that exist in the blood. This profile, together with clinical data collected from the patients is used to develop an algorithm (mathematical formula) that can predict response to treatment. Additionally, the algorithm tries to find an association between the protein profile and overall survival and the existence of adverse events (side effects) to the treatment. The clinical data is collected from the medical records of the patient for up to two years.
REC name
East Midlands - Derby Research Ethics Committee
REC reference
21/EM/0055
Date of REC Opinion
24 Mar 2021
REC opinion
Further Information Favourable Opinion